Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic changes in advanced gastrointestinal stromal tumor (GIST) patients during imatinib mesylate treatment.

Langenbeck's archives of surgery - 1 Nov 2006

Yeh Chun-Nan, Chen Tsung-Wen, Liu Feng-Yuan, Jan Yi-Yin, Chen Miin-Fu

Abstract excerpt

PURPOSE: Imatinib mesylate showed a sustained objective response in patients with advanced gastrointestinal stromal tumors (GISTs) since its introduction in 2001. Here we reported genetic changes during imatinib mesylate treatment especially when the patient had partial response or stationary disease. MATERIALS AND METHODS: Between 2001 and June 2005, 44 advanced GIST patients were treated with imatinib mesylate....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Benzamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Gastrointestinal Stromal Tumors

Share to Imatinib Mesylate

Share to Piperazines

Share to Proto-Oncogene Proteins c-kit

Share to Pyrimidines

Source

Identifiers

PMID: 17024483
DOI: 10.1007/s00423-006-0103-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic changes in advanced gastrointestinal stromal tumor (GIST) patients during imatinib mesylate treatment.PMID 17024483Read ↗

An Unexpected Response to Imatinib in a "Wild-Type" Gastrointestinal Stromal Tumor.Semantic proximity Read ↗

Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.Semantic proximity Read ↗

Genomic and transcriptomic analysis of imatinib resistance in gastrointestinal stromal tumors.Semantic proximity Read ↗

Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors.Semantic proximity Read ↗

Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).Semantic proximity Read ↗

Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesylate treatment.Semantic proximity Read ↗

Secondary resistance to imatinib mesylate in a patient with unresectable duodenal GIST without mutations in exons 9, 11, 13, or 17 of the c-kit protooncogeneSemantic proximity Read ↗

GIST under imatinib therapy.Semantic proximity Read ↗

MiR-320a downregulation is associated with imatinib resistance in gastrointestinal stromal tumorsSemantic proximity Read ↗

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.Semantic proximity Read ↗

Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations.Semantic proximity Read ↗

[Study on the mechanism of imatinib-induced resistance in gastrointestinal stromal tumors].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.